In animal models, d-allulose, d-glucose, or saline was orally administered along with mice chow. Cumulative food and water was measured over the course of 24hrs.  A base line fasted blood glucose measurement was taken. Then d-allulose, d-gluocose or saline was administered. Then they were injected with d-glucose, insulin or sodium pyruvate and blood samples were taken over the course of 4 hours and blood glucose levels were measured.

Iwasaki et al. found the administration of d-allulose stimulated GLP-1 release, inhibited food intake, and increased glucose tolerance in obese mice.

They conclude that since d-allulose has been approved by the FDA as a dietary supplement it may provide a safe and efficacious therapy to help with obesity, diabetes, and metabolic syndrome, possibly leading to associated cardiovascular and cerebral disorder improvement.